Quarterly report · Q1
3353.TEDINET S100U1RT
Period2024-03-01 → 2024-05-31
Filed2024-07-12
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥11.2bn | 2024-03-01 → 2024-05-31 | Cons. | Net sales |
| Revenue | ¥39.9bn | 2023-03-01 → 2024-02-29 | Cons. | Net sales (5-year summary) |
| Revenue | ¥8.7bn | 2023-03-01 → 2023-05-31 | Cons. | Net sales |
| Operating income | ¥429m | 2024-03-01 → 2024-05-31 | Cons. | Operating income |
| Operating income | ¥294m | 2023-03-01 → 2023-05-31 | Cons. | Operating income |
| Ordinary income | ¥431m | 2024-03-01 → 2024-05-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.8bn | 2023-03-01 → 2024-02-29 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥338m | 2023-03-01 → 2023-05-31 | Cons. | Ordinary income |
| Profit before tax | ¥671m | 2024-03-01 → 2024-05-31 | Cons. | Income before income taxes |
| Profit before tax | ¥375m | 2023-03-01 → 2023-05-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥429m | 2024-03-01 → 2024-05-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.0bn | 2023-03-01 → 2024-02-29 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥212m | 2023-03-01 → 2023-05-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥436m | 2024-03-01 → 2024-05-31 | Cons. | Profit loss |
| Net income | ¥224m | 2023-03-01 → 2023-05-31 | Cons. | Profit loss |
| Total assets | ¥31.8bn | at 2024-05-31 | Cons. | Assets |
| Total assets | ¥31.7bn | at 2024-02-29 | Cons. | Assets |
| Total assets | ¥28.1bn | at 2023-05-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥17.6bn | at 2024-05-31 | Cons. | Liabilities |
| Total liabilities | ¥17.8bn | at 2024-02-29 | Cons. | Liabilities |
| Net assets / equity | ¥14.2bn | at 2024-05-31 | Cons. | Net assets |
| Net assets / equity | ¥13.8bn | at 2024-02-29 | Cons. | Net assets |
| Net assets / equity | ¥12.7bn | at 2023-05-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥6.9bn | at 2024-05-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥7.7bn | at 2024-02-29 | Cons. | Cash and deposits |
| EPS (basic) | ¥114.23 | 2024-03-01 → 2024-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥276.7 | 2023-03-01 → 2024-02-29 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥56.42 | 2023-03-01 → 2023-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 42.7% | at 2024-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 41.8% | at 2024-02-29 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 43.2% | at 2023-05-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 44
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-03-01 → 2024-05-31 | −¥204m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-03-01 → 2024-05-31 | −¥204m |
| Reconciling Itemsreconciling | segment profit | 2024-03-01 → 2024-05-31 | −¥58m |
| jpcrp040300-q1r_E03443-000Dispensing Pharmacyreportable segment | revenue | 2024-03-01 → 2024-05-31 | ¥5.8bn |
| jpcrp040300-q1r_E03443-000Dispensing Pharmacyreportable segment | revenue external | 2024-03-01 → 2024-05-31 | ¥5.8bn |
| jpcrp040300-q1r_E03443-000Dispensing Pharmacyreportable segment | segment profit | 2024-03-01 → 2024-05-31 | ¥311m |
| jpcrp040300-q1r_E03443-000Health Carereportable segment | revenue | 2024-03-01 → 2024-05-31 | ¥1.9bn |
| jpcrp040300-q1r_E03443-000Health Carereportable segment | revenue external | 2024-03-01 → 2024-05-31 | ¥1.9bn |
| jpcrp040300-q1r_E03443-000Health Carereportable segment | revenue intersegment | 2024-03-01 → 2024-05-31 | ¥150,000 |
| jpcrp040300-q1r_E03443-000Health Carereportable segment | segment profit | 2024-03-01 → 2024-05-31 | ¥50m |
| jpcrp040300-q1r_E03443-000Medical Products Wholesalereportable segment | revenue | 2024-03-01 → 2024-05-31 | ¥3.6bn |
| jpcrp040300-q1r_E03443-000Medical Products Wholesalereportable segment | revenue external | 2024-03-01 → 2024-05-31 | ¥3.4bn |
| jpcrp040300-q1r_E03443-000Medical Products Wholesalereportable segment | revenue intersegment | 2024-03-01 → 2024-05-31 | ¥202m |
| jpcrp040300-q1r_E03443-000Medical Products Wholesalereportable segment | segment profit | 2024-03-01 → 2024-05-31 | ¥94m |
| jpcrp040300-q1r_E03443-000Real Estatereportable segment | revenue | 2024-03-01 → 2024-05-31 | ¥46m |
| jpcrp040300-q1r_E03443-000Real Estatereportable segment | revenue external | 2024-03-01 → 2024-05-31 | ¥45m |
| jpcrp040300-q1r_E03443-000Real Estatereportable segment | revenue intersegment | 2024-03-01 → 2024-05-31 | ¥1m |
| jpcrp040300-q1r_E03443-000Real Estatereportable segment | segment profit | 2024-03-01 → 2024-05-31 | ¥32m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-03-01 → 2024-05-31 | ¥11.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-03-01 → 2024-05-31 | ¥11.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-03-01 → 2024-05-31 | ¥204m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-03-01 → 2024-05-31 | ¥487m |
| Reconciling Itemsreconciling | revenue | 2023-03-01 → 2023-05-31 | −¥277m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-03-01 → 2023-05-31 | −¥277m |
| Reconciling Itemsreconciling | segment profit | 2023-03-01 → 2023-05-31 | −¥141m |
| jpcrp040300-q1r_E03443-000Dispensing Pharmacyreportable segment | revenue | 2023-03-01 → 2023-05-31 | ¥5.9bn |
| jpcrp040300-q1r_E03443-000Dispensing Pharmacyreportable segment | revenue external | 2023-03-01 → 2023-05-31 | ¥5.9bn |
| jpcrp040300-q1r_E03443-000Dispensing Pharmacyreportable segment | segment profit | 2023-03-01 → 2023-05-31 | ¥329m |
| jpcrp040300-q1r_E03443-000Health Carereportable segment | revenue | 2023-03-01 → 2023-05-31 | ¥2.0bn |
| jpcrp040300-q1r_E03443-000Health Carereportable segment | revenue external | 2023-03-01 → 2023-05-31 | ¥2.0bn |
| jpcrp040300-q1r_E03443-000Health Carereportable segment | revenue intersegment | 2023-03-01 → 2023-05-31 | ¥150,000 |
| jpcrp040300-q1r_E03443-000Health Carereportable segment | segment profit | 2023-03-01 → 2023-05-31 | ¥50m |
| jpcrp040300-q1r_E03443-000Medical Products Wholesalereportable segment | revenue | 2023-03-01 → 2023-05-31 | ¥1.1bn |
| jpcrp040300-q1r_E03443-000Medical Products Wholesalereportable segment | revenue external | 2023-03-01 → 2023-05-31 | ¥810m |
| jpcrp040300-q1r_E03443-000Medical Products Wholesalereportable segment | revenue intersegment | 2023-03-01 → 2023-05-31 | ¥275m |
| jpcrp040300-q1r_E03443-000Medical Products Wholesalereportable segment | segment profit | 2023-03-01 → 2023-05-31 | ¥23m |
| jpcrp040300-q1r_E03443-000Real Estatereportable segment | revenue | 2023-03-01 → 2023-05-31 | ¥47m |
| jpcrp040300-q1r_E03443-000Real Estatereportable segment | revenue external | 2023-03-01 → 2023-05-31 | ¥46m |
| jpcrp040300-q1r_E03443-000Real Estatereportable segment | revenue intersegment | 2023-03-01 → 2023-05-31 | ¥1m |
| jpcrp040300-q1r_E03443-000Real Estatereportable segment | segment profit | 2023-03-01 → 2023-05-31 | ¥34m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-03-01 → 2023-05-31 | ¥9.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-03-01 → 2023-05-31 | ¥8.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-03-01 → 2023-05-31 | ¥277m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-03-01 → 2023-05-31 | ¥435m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 364
| Item | Context | Value | Unit |
|---|---|---|---|
| Quarterly consolidated balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of income (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of comprehensive income (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding gain on reversal of advance received (text) | Prior1YTDDuration | Text · Plus | |
| Description of fact that quarterly statement of cash flows has not been prepared (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |